China Isotope & Radiation Corp. Announces Capital Increase for Sichuan Tongyuan

China Isotope & Radiation Corp. ( (HK:1763) ) has shared an update.

China Isotope & Radiation Corp. announced a capital increase for its subsidiary, Sichuan Tongyuan, involving contributions from 404 Chengdu and Chengdu NPIC. This transaction will raise Sichuan Tongyuan’s registered capital from RMB100 million to RMB123.46 million, with CNGT retaining an 81% stake, while 404 Chengdu and Chengdu NPIC will hold 10% and 9% respectively. This move, categorized as a connected transaction under Hong Kong’s Listing Rules, reflects strategic financial restructuring within the company, potentially enhancing its operational capacity and market positioning.

More about China Isotope & Radiation Corp.

China Isotope & Radiation Corporation operates in the isotope and radiation industry, focusing on the production and distribution of radioactive isotopes and related products. The company is primarily engaged in providing services and products for medical, industrial, and scientific applications, with a significant market presence in China.

YTD Price Performance: 19.71%

Average Trading Volume: 169,373

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.16B

For a thorough assessment of 1763 stock, go to TipRanks’ Stock Analysis page.